Early research (Phase 1)Study completedNCT01814839
What this trial is testing
A Phase 1, Single- and Multi-Dose, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered ALN-TTRSC (Revusiran) in Healthy Volunteers
Who this might be right for
TTR-mediated Amyloidosis
Alnylam Pharmaceuticals 85